Therapeutic Asset Ratings

247 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Zorifertinib Lung Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Zorifertinib Neoplastic Meningitis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Zorifertinib Zorifertinib	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Zuberitamab Marginal Zone Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (53)
Sacituzumab Tirumotecan Pancreatic Ductal Adenocarcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (52)
ibi363 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (52)
Iparomilimab Neoadjuvant Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	CCC (52)
Tuvonralimab Neoadjuvant Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	CCC (52)
Aitua Combination Antibody Primary Peritoneal Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
Envafolimab Lung Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Neoadjuvant Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
Iparomlimab Pancreatic Adenocarcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
ltc004 Malignant Pancreatic Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
Utidelone Neoadjuvant Therapy	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (51)
es014 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (50)
Telpegfilgrastim Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (48)
Axitinib Atorvastatin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Axitinib Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Ivonescimab Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Lipitor Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Sk-Nk Cell Ascites	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Sk-Nk Cell Ovarian Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Toripalimab Atorvastatin	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Toripalimab Thyroid Gland Papillary Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Adebrelimab Breast Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CC (46)

Showing 126 to 150 of 247 assets

PreviousPage 6 of 10Next